^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Acute Lymphocytic Leukemia
    Drug:Idhifa (enasidenib) (IDH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASH 2021
    Title:

    Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify TrialClinically Relevant Abstract

    Published date:
    11/04/2021
    Excerpt:
    This international, multicenter, open-label trial enrolled pts aged ≥60 yrs with ECOG PS ≤2 and mIDH2 AML R/R...Among E-E pts (ENA, n = 133; CCR, n = 110), OS was improved with ENA….In pts with late-stage mIDH2 R/R AML, ENA was associated with clinically meaningful improvements in morphologic response...
    DOI:
    10.1182/blood-2021-147593
    Trial ID:
    IDHENTIFY
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Acute Myelogenous Leukemia)
    New
    Excerpt:
    IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDAapproved test